EMA committee concludes diclofenac poses similar risks as COX-2 inhibitors

The committee says the benefits of diclofenac exceed the known risks and that physicians should take the same precautions to minimize thromboembolic risk as they do with patients treated with selective COX-2 inhibitors.
Source: theHeart.org - Category: Cardiology Source Type: news